Quick10K

⚲

Novo Integrated Sciences

Filings

10-Q	2020-05-31	Filed 2020-07-14
10-Q	2020-02-29	Filed 2020-04-20
10-Q	2019-11-30	Filed 2020-01-13
10-K	2019-08-31	Filed 2019-11-20
10-Q	2019-05-31	Filed 2019-07-11
10-Q	2019-02-28	Filed 2019-04-11
10-Q	2018-11-30	Filed 2019-01-11
10-K	2018-08-31	Filed 2018-11-06
10-Q	2018-05-31	Filed 2018-07-11
10-Q	2018-02-28	Filed 2018-04-12
10-Q	2017-11-30	Filed 2018-01-12
10-K	2017-08-31	Filed 2017-12-08
10-Q	2017-05-31	Filed 2017-07-24
10-Q	2017-03-31	Filed 2017-04-14
10-K	2016-12-31	Filed 2017-03-07
10-Q	2016-09-30	Filed 2016-10-31
10-Q	2016-06-30	Filed 2016-07-22
10-Q	2016-03-31	Filed 2016-04-29
10-K	2015-12-31	Filed 2016-03-25
10-Q	2015-09-30	Filed 2015-10-30
10-Q	2015-06-30	Filed 2015-07-31
10-Q	2015-03-31	Filed 2015-05-01
10-K	2014-12-31	Filed 2015-03-27
10-Q	2014-09-30	Filed 2014-11-05
10-Q	2014-06-30	Filed 2014-08-01
10-Q	2014-03-31	Filed 2014-05-19
10-K	2013-12-31	Filed 2014-04-16
10-Q	2013-09-30	Filed 2013-11-19
10-Q	2013-06-30	Filed 2013-08-16
10-Q	2013-03-31	Filed 2013-05-20
10-K	2012-12-31	Filed 2013-04-15
10-Q	2012-09-30	Filed 2012-11-23
10-Q	2012-06-30	Filed 2012-08-20
10-Q	2012-03-31	Filed 2012-05-15
10-K	2011-12-31	Filed 2012-04-06
10-Q	2011-09-30	Filed 2011-11-21
10-Q	2011-06-30	Filed 2011-08-15
10-Q	2011-03-31	Filed 2011-05-13
10-K	2010-12-31	Filed 2011-03-31
10-Q	2010-09-30	Filed 2010-11-15
10-Q	2010-06-30	Filed 2010-08-16
10-Q	2010-03-31	Filed 2010-05-17
10-K	2009-12-31	Filed 2010-04-14

Reports

8-K	2020-11-23	Amend Bylaw, Exhibits
8-K	2020-11-09	Amend Bylaw, Shareholder Vote
8-K	2020-10-19	Regulation FD
8-K	2020-08-06	Officers, Regulation FD, Exhibits
8-K	2020-07-21	Sale of Shares
8-K	2020-04-07
8-K	2020-03-20
8-K	2020-03-09
8-K	2020-02-04
8-K	2019-12-17
8-K	2019-10-23
8-K	2019-09-24
8-K	2019-09-11
8-K	2019-03-06
8-K	2019-02-26
8-K	2019-02-20
8-K	2019-01-31
8-K	2019-01-14
8-K	2018-12-18
8-K	2018-11-30
8-K	2018-11-23
8-K	2018-11-14
8-K	2018-10-23
8-K	2018-10-17
8-K	2018-10-10
8-K	2018-07-27
8-K	2018-05-31
8-K	2018-04-08
8-K	2018-03-19
8-K	2018-03-15
8-K	2018-01-30
8-K	2018-01-16
8-K	2017-12-29
8-K	2017-12-26

Novo Integrated Sciences Financials

NVOS Metrics, Comps, Filings

Quarterly | Annual

Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin


Comps ($'000 TTM)	Market Cap	Gross Margin	EV/EBITDA	Ret on Assets	Assets	Liabilities	Revenue	G Profit	Net Income	EBITDA	EV
Castle Biosciences (CSTL)	334,822	85%	35.2	4%	113,200	30,864	25,513	21,812	4,580	7,539	265,251
New York & Company (NWY)	330,180	29%	-12.5	-4%	486,431	430,014	850,241	249,177	-21,388	-21,254	264,615
Invesco DB US Dollar Index Bullish Fund (UUP)	329,522		16.0	6%	330,667	203	0	0	20,586	20,596	329,522
Zynex (ZYXI)	324,063	62%	25.1	37%	24,724	8,332	40,647	25,317	9,167	12,416	312,129
Atreca (BCEL)	310,800		-4.3	-16%	212,718	7,723	0	0	-33,792	-33,362	143,374
Corium (CORI)	305,900	0%	-4.9	-50%	112,131	87,239	37,693	0	-56,540	-45,465	223,763
Exantas Capital (RSO)	303,730	0%	17.4	2%	2,472,193	1,912,167	46,751	0	39,535	123,013	2,145,860
Energy XXI Gulf Coast (EGC)	300,174	0%	-1.3	-30%	1,032,246	929,173	454,101	0	-313,739	-174,942	228,492
South Plains Financial (SPFI)	298,399		1.1	1%	2,795,582	2,496,555	0	0	19,111	49,907	53,754
Focus Universal (FCUV)	294,910	24%	-109.6	-32%	8,252	466	995	243	-2,668	-2,665	292,150
Novo Integrated Sciences (NVOS)	234,765	50%	-426.2	-2%	31,682	6,368	7,002	3,529	-628	-545	232,287
Parker Drilling (PKD)	283,593	10%	-10.7	-19%	667,657	312,841	602,659	60,498	-124,691	-33,643	359,519
Stereotaxis (STXS)	282,894	80%	-72.5	-8%	43,306	14,588	22,010	17,619	-3,507	-3,466	251,244
Axovant Sciences (AXON)	276,117		-1.5	-165%	102,188	82,309	0	0	-168,944	-157,405	240,391
Invesco DB Oil Fund (DBO)	267,596		6.9	15%	258,073	7,694	0	0	38,599	38,637	267,596
Kush Bottles (KSHB)	386	18%	-0.2	-22%	160,659	57,122	101,982	18,474	-34,905	-31,261	6,651
Invesco CurrencyShares Euro Trust (FXE)	254,678		-1.7	-1%	253,883	158	0	0	-1,435	-469	795
United Health Products (UEEC)	252,522	60%	-58.8	-1,768%	234	526	25	15	-4,136	-4,292	252,434
Satsuma Pharmaceuticals (STSA)	252,234		-17.0	-6%	127,544	9,423	0	0	-8,260	-8,139	138,334
CV Sciences (CVSI)	250,868	70%	-25.4	-18%	56,538	23,295	44,368	30,938	-9,924	-9,315	236,630


Balance Sheet ($'000)	2011-06-30	2011-09-30	2011-12-31	2012-03-31	2012-09-30	2012-12-31	2013-03-31	2013-06-30	2013-09-30	2013-12-31	2014-03-31	2014-06-30	2014-09-30	2014-12-31	2015-03-31	2015-06-30	2015-09-30	2015-12-31	2016-03-31	2016-06-30	2016-09-30	2016-12-31	2017-03-31	2017-05-31	2017-08-31	2017-11-30	2018-02-28	2018-05-31	2018-08-31	2018-11-30	2019-02-28	2019-05-31
Cash	7	9	12	11	24	6	25	0	1	3	12	0	6	2	9	8	9	14	34	17	13	54	15	1,674	1,897	1,296	1,037	864	676	929	2,374	2,478
Accounts Receivable																								855	1,129	1,289	1,349	1,312	1,338	1,405	1,379	1,383
Inventory
PP&E	52	51	7	6	19	70	16	15	14	70	12	10	9	37	6	0	0	1						520	571	559	609	641	729	790	800	806
Assets	178	164	26	226	275	35	49	22	379	358	295	201	133	23	29	22	22	28	47	31	27	70	37	5,389	5,514	4,958	5,072	4,840	4,743	5,062	29,081	31,682
Accounts Payable	134	119	116	75	124	118	120	163	160	146	134	161	77	83	101	56	12	13	27	9	3	20	5	1,895	1,703	1,575	1,744	1,310	1,308	1,368	1,254	1,284
Long-Term Debt					649	687	813	773	446	117	192	244	272	308	0	0	0	0						406	428	408	411	406	0	0	0	0
Liabilities	2,058	2,244	2,354	2,055	797	832	974	957	1,263	1,306	1,221	1,345	714	648	101	56	12	13	27	9	3	20	5	9,938	9,803	9,339	4,719	4,556	4,570	4,545	4,252	6,368
Stockholders' Equity	-1,879	-2,080	-2,328	-1,829	-522	-797	-925	-935	-884	-948	-925	-1,145	-580	-626	-73	-34	10	15	20	22	24	50	32	-4,531	-4,268	-4,358	379	310	201	551	24,866	25,351


Income Statement ($'000)	2011-06-30	2011-09-30	2011-12-31	2012-03-31	2012-09-30	2012-12-31	2013-03-31	2013-06-30	2013-09-30	2013-12-31	2014-03-31	2014-06-30	2014-09-30	2014-12-31	2015-03-31	2015-06-30	2015-09-30	2015-12-31	2016-03-31	2016-06-30	2016-09-30	2016-12-31	2017-03-31	2017-05-31	2017-08-31	2017-11-30	2018-02-28	2018-05-31	2018-08-31	2018-11-30	2019-02-28	2019-05-31
Revenue																								2,090	2,220	2,254	2,310	2,323		2,312	2,200	2,490
Cost of Revenue																								1,377	1,255	1,408	1,338	1,418	1,338	1,428	1,321	1,557
Gross Profit																								713	966	846	971	905	834	884	880	933
R&D	87	0	43	0		0	0	0	0	0	0	0	0	0	0	0	25	0	0		0	0
SG&A																								974	928	1,018	2,010	1,082	927	1,099	958	996
Tax																								0	0	0	0	0	0	0	0	0
Net Income	-485	-501	-417	-409	-199	-165	-243	-283	-169	-192	-146	-327	-209	-328	-2,360	-362	-13	-35	-68	-17	-37	-42	-37	-357	-616	-357	-1,375	-218	-158	-251	-120	-99


Cash Flow ($'000)	2011-06-30	2011-09-30	2011-12-31	2012-03-31	2012-09-30	2012-12-31	2013-03-31	2013-06-30	2013-09-30	2013-12-31	2014-03-31	2014-06-30	2014-09-30	2014-12-31	2015-03-31	2015-06-30	2015-09-30	2015-12-31	2016-03-31	2016-06-30	2016-09-30	2016-12-31	2017-03-31	2017-05-31	2017-08-31	2017-11-30	2018-02-28	2018-05-31	2018-08-31	2018-11-30	2019-02-28	2019-05-31
Cash Operating		-35		-145		-45	-49	-90	-70	-40	-42	-32	-31	-40	-26	-85	-50	-15	-21	-46	-20	-23	-54	-298	-724	-352	-421		-94	-163	-297	-71
Cash Investing		0		-198		0	0	0	0	0	0	0	0	-1					0	0	0	0	0	-392	-750	-24	-83		-94	-74	-227	-404
Cash Financing		37		342		28	68	65	71	43	51	20	37	38	33	85	50	20	40	30	15	65	15	2,160	3,023	-184	-286		11	497	1,940	639